AChR-Ab+ Generalized Myasthenia Gravis When Initial Immunotherapy Has Not Reduced the QMG Score
This protocol addresses generalized myasthenia gravis in patients who are seropositive for anti-acetylcholine receptor antibodies (AChR-Ab+) and who have not achieved an adequate reduction in the quantitative MG (QMG) score following an initial course of immunotherapy.
Generalized myasthenia gravis with confirmed antibodies to acetylcholine receptors (AChR-Ab+). In nonthymomatous patients aged 18–50 years, extended transsternal thymectomy is considered early in the disease to improve clinical outcomes and to reduce immunotherapy requirements and hospitalizations for disease exacerbations.
An adequate trial of immunotherapy — with thymectomy considered in eligible patients — did not achieve meaningful reduction in the QMG score. This protocol defines the next step when that target is not reached.
Steroid-sparing immunosuppressive therapy forms the basis of this next step. The clinical goals are to achieve and maintain minimal manifestation (MM) status and to reduce the required prednisone dose. The full agent selection, sequencing, and criteria are in the complete protocol.
References
In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations.
Similar proportions of both groups achieved MM status, and there were no differences in QMG or MG-activity of daily living (MG-ADL) scores between the groups.
View source ↗